Evidence map›Paper›PMID 39877562›Full record

ArticleBJUI compass2025

Clinical validation of a biopsy-based six-gene signature prognostic for aggressive prostate cancer.

Agnieszka Krzyzanowska, Debra F Higgins, Stephen Barron, Tony Loughman, Amanda O'Neill, Katherine M Sheehan, Chan-Ju Angel Wang, Bozena Fender, Leah McGuire, Joanna Fay and 5 more

Abstract read
In one paragraph

Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Agnieszka KrzyzanowskaDepartment of Translational Medicine, Division of Urological Cancers, Faculty of Medicine Lund University Lund Sweden.ORCID https://orcid.org/0000-0002-1288-7054
Debra F HigginsOncoAssure Ltd, NovaUCD Dublin Ireland.ORCID https://orcid.org/0000-0002-3205-2409
Stephen BarronOncoAssure Ltd, NovaUCD Dublin Ireland.
Tony LoughmanOncoAssure Ltd, NovaUCD Dublin Ireland.
Amanda O'NeillUCD School of Medicine, UCD Conway Institute of Biomolecular and Biomedical Research University College Dublin Dublin Ireland.
Katherine M SheehanPathology, RCSI Education and Research Centre Beaumont Hospital Dublin Ireland.
Chan-Ju Angel WangOncoAssure Ltd, NovaUCD Dublin Ireland.
Bozena FenderOncoAssure Ltd, NovaUCD Dublin Ireland.
Leah McGuireOncoAssure Ltd, NovaUCD Dublin Ireland.
Joanna FayRCSI Biobank, RCSI Education and Research Centre Beaumont Hospital Dublin Ireland.
Anthony O'GradyPathology, RCSI Education and Research Centre Beaumont Hospital Dublin Ireland.
Des O'LearyOncoAssure Ltd, NovaUCD Dublin Ireland.
R William WatsonUCD School of Medicine, UCD Conway Institute of Biomolecular and Biomedical Research University College Dublin Dublin Ireland.ORCID https://orcid.org/0000-0001-8831-3244
Anders BjartellDepartment of Translational Medicine, Division of Urological Cancers, Faculty of Medicine Lund University Lund Sweden.ORCID https://orcid.org/0000-0002-5761-3786
William M GallagherOncoAssure Ltd, NovaUCD Dublin Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to clinically validate the six-gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods: MCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, Results: Biopsy MCRS was significantly prognostic ( Conclusion: Biopsy-based MCRS improves risk stratification over standard clinical and pathological information and optimises patient management after diagnosis of prostate cancer.

Indexed as

gene expression signaturemolecular risk scorepatient managementprognosisprostate cancerrisk stratificationtreatment decisions

Identifiers

PMID39877562
PMCPMC11771492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.